ACCENDRA HEALTH INC/VA/ (ACH)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-03-24

Key Insights

The reporting person, Heath H. Galloway, surrendered 9,347 shares to the issuer to satisfy tax withholding obligations related to the vesting of restricted stock grants. This indicates the executive is not selling shares for profit but rather using them to cover tax liabilities.
Following the transaction, Galloway still holds 169,094 shares of the issuer's common stock, suggesting he remains invested in the company's long-term success.
The transaction was executed on March 20, 2026, which is the date of the earliest transaction reported in the filing.

Insider Trading Filed: 2026-03-24

Key Insights

Insider Perry A. Bernocchi, the EVP and Chief Operating Officer, sold 20,841 shares of ACCENDRA HEALTH INC/VA/ (ACH) stock on March 20, 2026 to cover tax withholding obligations related to restricted stock vesting.
The stock sale represents a small fraction (approximately 6%) of Bernocchi's total beneficial ownership, which remains at 321,821 shares.
This routine insider sale may not indicate any significant change in management's view of the company's prospects, but investors should monitor any further insider trading activity.

Insider Trading Filed: 2026-03-24

Key Insights

The reporting person, Jonathan A. Leon, who is the EVP & CFO of Accendra Health Inc/VA/, sold 11,286 shares of the company's common stock on March 20, 2026 at a price of $2.03 per share. This may indicate some insider selling activity.
Following the reported transaction, the reporting person still holds 292,303 shares of the company's common stock, indicating they maintain a significant ownership stake.
The sale of shares was to satisfy tax withholding obligations in connection with the vesting of restricted stock granted to the reporting person, a common practice for executives.

Insider Trading Filed: 2026-03-24

Key Insights

Edward A. Pesicka, the President and CEO of Accendra Health Inc., surrendered 58,945 shares to the company to satisfy tax withholding obligations related to the vesting of restricted stock.
Pesicka continues to beneficially own a substantial amount of Accendra Health stock, with 1,090,477 shares following the reported transaction.
This transaction suggests that the reporting person may have confidence in the company's future performance, as they have not fully divested their stake.

Annual Report Filed: 2026-02-20

Key Insights

Accendra Health reported strong revenue growth of 1.1% year-over-year, driven by increased sales in their wound care and diabetes product segments.
The company saw a decline in operating margins due to higher professional fees and IT strategic initiatives, which could impact profitability going forward.
Accendra has significant geographic concentration risk, with over 80% of revenue coming from just four states (CA, IL, NY, OR), making the business vulnerable to regional market changes.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.